Navigation Links
Marsha Fanucci Joins Ironwood Board of Directors
Date:10/27/2009

CAMBRIDGE, Mass., Oct. 27 /PRNewswire/ -- Ironwood Pharmaceuticals, Inc. today announced that Marsha Fanucci has joined its Board of Directors. Ms. Fanucci served at Millennium Pharmaceuticals, Inc. from 2000-2009 in a number of senior positions, including chief financial officer and senior vice president of strategy, vice president of finance and strategy, and vice president of corporate development and strategy. During her tenure as CFO, Ms. Fanucci led Millennium through a series of strategic focusing processes, advancing the company from an investment stage company to a profitable industry leader that was acquired by Takeda Pharmaceutical Company in 2008 for $8.8 billion. Previously, Ms. Fanucci was vice president of corporate development and strategy at Genzyme Corporation, and prior to that, vice president and director at Arthur D. Little, Inc.

(Logo: http://www.newscom.com/cgi-bin/prnh/20081006/NEM080ALOGO )

"We are thrilled to integrate Marsha's expertise into our board dynamic. Marsha shares with our other board members business savvy, an owner-orientation, and a strong commitment to fostering a culture with a high degree of integrity," said Peter Hecht, CEO of Ironwood. "We look forward to tapping into her deep leadership experience managing innovation and integrating corporate strategy, finance, and operations."

"I am excited to be joining Ironwood as the company strives to bring linaclotide to patients and advance its development pipeline," said Ms. Fanucci. "I look forward to working with the board and management team to build a great entrepreneurial pharmaceutical company."

Ms. Fanucci has a B.S. in pharmacy from West Virginia University Medical School and an M.B.A. from Northeastern University. She serves on the board of directors of Momenta Pharmaceuticals, where she chairs the Audit Committee.

About Ironwood Pharmaceuticals

Ironwood Pharmaceuticals (www.ironwoodpharma.com) is an entrepreneurial pharmaceutical company dedicated to the art and science of great drugmaking. Linaclotide, the Company's first-in-class compound, is being evaluated in a confirmatory Phase 3 program for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic constipation. Ironwood also has a growing pipeline of additional drug candidates in earlier stages of development. Ironwood has raised $306 million in private equity financing and is located in Cambridge, Massachusetts.

    Contact:
    Susan Brady
    Corporate Communications
    617.621.8304
    sbrady@ironwoodpharma.com

SOURCE Ironwood Pharmaceuticals, Inc.


'/>"/>
SOURCE Ironwood Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. General Wesley Clark Joins Immtech as Consulting Strategic Advisor
2. Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign
3. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
4. Actress and Mother Jennifer Garner Joins American Lung Association to Encourage Americans to Get an Influenza Vaccination
5. MedicAlert Foundation Joins The Alzheimers Association to Offer MedicAlert(R) + Alzheimers Association Safe Return(R) - Live 24-Hour Emergency Response for Wandering and Medical Emergencies
6. Olympic Gold Medalist Kristi Yamaguchi Joins American Lung Association of Michigan to Address Seriously Low Vaccination Rates; Urge Metro-Detroiters to Get Immunized This Season
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
9. Dr. Harriet Robinson Joins GeoVax Team as V.P. of R & D to Accelerate AIDS Vaccine Trials Program
10. Dr. Peter Nash, Ph.D. Joins Mach One Corporation as Chief Scientist
11. Judith Quinlan Joins Cytel as Vice President, Adaptive Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/24/2016)... 2016 Een app die artsen ... collectief patiënten kunnen behandelen, hun kennis kunnen delen en ... de nieuwe en revolutionaire MDLinking App, ontwikkeld door een ... dr. Hans Flu en oncologisch chirurg dr. Gijs ... is, wordt op dinsdag 24 mei officieel gepresenteerd op ...
(Date:5/23/2016)... 23, 2016 According to ... Development, Growth and Demand Forecast to 2022 - ... by Application (Drug Discovery and Development, Proteomics, Clinical ... Life Science and Biotechnology, Academic and Research Institute, ... the global mass spectrometry market was ...
(Date:5/23/2016)... , May 23, 2016 Gamida ... the treatment of cancer and orphan genetic diseases, announced ... to $4.4 million from the Israel Innovation Authority (formerly ... Ministry of Economy and Industry. The mission of the ... in various industries, including science and technology, while stimulating ...
Breaking Medicine Technology:
(Date:5/24/2016)... ... ... Sterling Global Products is launching a Kickstarter campaign focused on “PAW Patrol ... campaign kick-off video is located via this link https://youtu.be/WsO4qz2odco . The campaign will ... raise $1,000 per day for a total of $25,000. The funds will be used ...
(Date:5/24/2016)... , ... May 24, 2016 , ... ... of its services to provide one resource, from start to finish, for Life ... Life Safety Statement of Condition surveys requested by the Joint Commission, and fire ...
(Date:5/24/2016)... , ... May 24, 2016 , ... ... organization, is pleased to welcome new Partner Firm Austin & Co., Inc. ... approach to insurance, employee benefits, HR consulting, benefits technology, and beyond. As ...
(Date:5/24/2016)... ... May 24, 2016 , ... How to Write Error Free Procedures, ... http://www.fdanews.com/humanerrordrugdevice , Human error is known to be the major cause of quality ... ever be totally eliminated, many human performance problems can be prevented. , How to ...
(Date:5/24/2016)... ... (PRWEB) May 24, 2016 -- Grow Healthy ... Advisory Board. Joining the Grow Healthy Advisory Board team are ... embody the mission of our organization and bring talent, expertise and ... as we continue to expand our footprint as the leader in ...
Breaking Medicine News(10 mins):